Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience.
暂无分享,去创建一个
T. Bekaii-Saab | R. McWilliams | W. Ma | A. Desai | H. Babiker | A. Mahipal | J. Starr | M. Sonbol | J. Stauffer | S. Chakrabarti | Tucker Coston
[1] G. Prager,et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. , 2023, European journal of cancer.
[2] M. Ychou,et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. , 2022, JAMA oncology.
[3] L. Bucheit,et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer , 2022, Journal for ImmunoTherapy of Cancer.
[4] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[5] K. Lim,et al. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab Plus Ipilimumab in Periampullary Adenocarcinoma. , 2021, The oncologist.
[6] Yutaka Suzuki,et al. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer , 2021, JCI insight.
[7] A. Scarpa,et al. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different? , 2021, Gut.
[8] A. Lampis,et al. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer , 2020, Genes.
[9] Zhiqiang Wu,et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. , 2020, Cytotherapy.
[10] E. Jaffee,et al. The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities , 2020, Nature Reviews Clinical Oncology.
[11] L. Wood,et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications , 2020, Gut.
[12] M. Karamouzis,et al. Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.
[13] D. Torigian,et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] Myung Ah Lee,et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[15] A. Scarpa,et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Berlin,et al. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors , 2019, Oncology.
[17] E. Zervos,et al. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer , 2018, International journal of molecular sciences.
[18] D. Torigian,et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.
[19] T. Walsh,et al. Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. , 2018, American journal of human genetics.
[20] D. Mahalingam,et al. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. , 2018, Journal of gastrointestinal oncology.
[21] Huamin Wang,et al. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma , 2017, JAMA surgery.
[22] Zhiqiang Wu,et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers , 2017, Protein & Cell.
[23] T. Conroy,et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] A. Hinke,et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.
[25] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[26] Wenchuan Wu,et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer , 2012, Clinical and Experimental Medicine.
[27] Sylvia Janetzki,et al. Improved Endpoints for Cancer Immunotherapy Trials , 2010, Journal of the National Cancer Institute.